Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540002 | 0.83 | DRD2 (0.44) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL6207099 | 0.82 | PPARG (0.43) | MRGPRX4DRD2DRD3HTR1DDRD4 | |
| SCHEMBL7601041 | 0.81 | DRD2 (0.39) | MRGPRX4DRD2DRD3HTR1DDRD4 | |
| Iodide SCHEMBL7773907 | 0.81 | PPARG (0.42) | MRGPRX4DRD2DRD3HTR1DDRD4 | |
| SCHEMBL27635410 | 0.81 | MRGPRX4 (0.44) | MRGPRX4P2RX7CCR4NOTUMEPAS1 | |
| SCHEMBL28115604 | 0.80 | DRD2 (0.40) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL19948204 | 0.79 | FABP1 (0.38) | MRGPRX4DRD2DRD3HTR1DDRD4 | |
| SCHEMBL29428702 | 0.79 | FABP1 (0.38) | MRGPRX4DRD2DRD3HTR1DDRD4 | |
| SCHEMBL1707904 | 0.78 | ALDH1A1 (0.44) | DRD2DRD3HTR1DDRD4EPAS1 | |
| SCHEMBL28115113 | 0.78 | PNMT (0.42) | DRD2DRD3HTR1DDRD4HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | MRGPRX4 316/4885P2RX7 659/4885DRD2 338/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | MRGPRX4 840/4885P2RX7 560/4885DRD2 2/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MRGPRX4 840/4885P2RX7 560/4885DRD2 2/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MRGPRX4 840/4885P2RX7 560/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.